经工程改造以克服肿瘤免疫逃逸的肿瘤特异性T细胞在复发霍奇金淋巴瘤患者中诱导临床缓解
这项剂量递增研究纳入8例EB病毒阳性霍奇金淋巴瘤患者,输注表达显性负性TGF-β受体2(DNRII)的EB病毒抗原特异性T细胞(DNRII-LSTs),未预处理化疗。DNRII-LSTs在体外抵抗TGF-β抑制并保持抗原特异性活性,输注后外周血转基因信号最高增加100倍,持续≥4年,无急性或长期毒性;7例可评估活动性疾病患者中4例获临床缓解,2例完全缓解持续>4年。
要点
- DNRII-LSTs在体外抵抗抑制性浓度TGF-β并保留肿瘤抗原特异性活性。
- 输注后外周血转基因信号最高增加100倍,DNRII-LSTs持续≥4年,无急性或长期毒性。
- 7例可评估活动性疾病患者中4例获临床缓解,2例完全缓解持续>4年。
核心结论
- 抵抗TGF-β的肿瘤特异性T细胞可在未预处理化疗的霍奇金淋巴瘤患者中安全扩增并持续存在。
- DNRII-LSTs甚至可在耐药疾病患者中诱导完全缓解。
- 表达DNRII可能对许多利用该免疫逃逸机制的其它肿瘤有用。
研究设计与样本
- 剂量递增研究,纳入8例EB病毒阳性霍奇金淋巴瘤患者。
- 患者接受2至12剂DNRII-LSTs,剂量范围为2×10^7至1.5×10^8细胞/m2。
- DNRII-LSTs为表达显性负性TGF-β受体2、靶向EB病毒潜伏膜蛋白(LMP)-1和LMP-2的T细胞。
- 输注前未使用淋巴细胞清除性化疗。
主要发现
- DNRII-LSTs在体外对抑制性浓度TGF-β抵抗并保留肿瘤抗原特异性活性。
- 输注后外周血转基因T细胞信号经定量聚合酶链反应检测最高增加100倍,功能性LMP特异性T细胞频率相应增加。
- 扩增未伴随任何急性或长期毒性。
- DNRII-LSTs持续存在长达≥4年。
- 7例可评估活动性疾病患者中4例获临床缓解,其中2例完全缓解持续>4年,包括1例对未修饰肿瘤靶向T细胞仅获部分缓解的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Transforming growth factor-β (TGF-β) production in the tumor microenvironment is a potent and ubiquitous tumor immune evasion mechanism that inhibits the expansion and function of tumor-directed responses; therefore, we conducted a clinical study to discover the effects of the forced expression of a dominant-negative TGF-β receptor type 2 (DNRII) on the safety, survival, and activity of infused tumor-directed T cells. Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 doses of between 2 × 107 and 1.5 × 108 cells/m2 of DNRII-expressing T cells with specificity for the Epstein Barr virus-derived tumor antigens, latent membrane protein (LMP)-1 and LMP-2 (DNRII-LSTs). Lymphodepleting chemotherapy was not used before infusion. Results DNRII-LSTs were resistant to otherwise inhibitory concentrations of TGF-β in vitro and retained their tumor antigen-specific activity. After infusion, the signal from transgenic T cells in peripheral blood increased up to 100-fold as measured by quantitative polymerase chain reaction for the transgene, with a corresponding increase in the frequency of functional LMP-specific T cells. Expansion was not associated with any acute or long-term toxicity. DNRII-LSTs persisted for up to ≥ 4 years. Four of the seven evaluable patients with active disease achieved clinical responses that were complete and ongoing in two patients at > 4 years, including in one patient who achieved only a partial response to unmodified tumor-directed T cells. Conclusion TGF-β-resistant tumor-specific T cells safely expand and persist in patients with Hodgkin lymphoma without lymphodepleting chemotherapy before infusion. DNRII-LSTs can induce complete responses even in patients with resistant disease. Expression of DNRII may be useful for the many other tumors that exploit this potent immune evasion mechanism.
引用
- Bollard CM, Tripic T, Cruz CR, et al. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018. PMID: 29315015. doi:10.1200/JCO.2017.74.3179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。